Responsibility. Subject to the terms and conditions of this Agreement, Acadia (and its Affiliates and Sublicensees, as applicable) shall be responsible, at its sole cost and expense, for the Commercialization of all Licensed Products in the Field in the Territory.

Kyorin Development Responsibility. Subject to the responsibilities of the JSC and the other terms of this Agreement, Kyorin will be responsible for conducting or having conducted, in accordance with the Kyorin Development Plan and the Global Development Plan, the Development of the Licensed Products in the Field solely for purposes of obtaining and maintaining Regulatory Approval of Licensed Products in the Kyorin Territory and for Commercialization of such Licensed Products in the Kyorin Territory. Kyorin will bear one hundred percent (100%) of the Development Costs incurred by Kyorin in connection with the foregoing Development activities. If aTyr and Kyorin agree in writing that aTyr will perform any specific activities that are solely to support Development required to obtain or maintain Regulatory Approval of Licensed Products in the Kyorin Territory or for Commercialization of such Licensed Products in the Kyorin Territory and incur any Development Costs for such Development activities, Kyorin will reimburse amounts incurred by aTyr under this [Section 3.1.1] in accordance with the process set forth in Section 8.6. For clarity, Kyorin will have no obligation to bear any cost for the Development of the Licensed Products in the aTyr Territory for purposes of obtaining and maintaining Regulatory Approval of such Licensed Products in the aTyr Territory.

Clinical Candidate Development; Responsibility. Subject to the terms and conditions of this Agreement, for each of the [[Unknown Identifier]] and ​ Targets, Acadia will be responsible for carrying out and funding the Development (subject to Stoke carrying out those activities assigned to Stoke under the applicable Research Plan as described above) of the Clinical Candidates Directed Against such Targets in the Territory (the “[[Unknown Identifier]] Development Program” and “​ Development Program,” respectively). Before Acadia conducts any Development activities for Licensed Products for the [[Unknown Identifier]] and ​ Targets, Acadia must have a Development Plan in place. Acadia shall conduct each Development Program pursuant to a plan setting forth, with respect to each Clinical Candidate for such Development Program, # the specific Development activities (including Clinical Trials) to be conducted by Acadia, # planned timelines for conducting such Development activities, and # a strategy and timeline for obtaining Regulatory Approval of a Licensed Product corresponding to such Clinical Candidate throughout the Territory (the “[[Unknown Identifier]] Development Plan” and “​ Development Plan,” respectively). Acadia will submit an initial Development Plan for each Development Program to the JDC for review and comment within ​ following the relevant [[Unknown Identifier]] Technology Transfer or ​ Technology Transfer. Following review and comment by the JDC, the JDC shall submit the initial Development Plan for a Development Program to the JSC for the JSC’s review and approval. For clarity, during the Research Term or prior to the conclusion of a Research Program, Acadia may simultaneously perform certain Development activities (e.g., natural history studies) for the Licensed Products with respect to the [[Unknown Identifier]] and ​ Targets, in each case, pursuant to a Development Program and corresponding Development Plan.

Zai Lab Development Responsibility. As between the Parties, Zai Lab will be solely responsible for the Development of the Licensed Product(s) in the Field throughout the Zai Lab Territory, ​. Zai Lab will use Commercially Reasonable Efforts to Develop the Licensed Product(s) to obtain Regulatory Approval in the Zai Lab Territory for ​ in accordance with the Development Plan and in compliance with Applicable Law, including GCP and ICH Requirements.

Responsibility. Licensee may use the Inventory provided by [[AstraZeneca:Organization]] solely for the development of Licensed Products pursuant to this Agreement and shall not make any Inventory available to any Third Party except as expressly permitted herein. As between the Parties, Licensee shall have the sole responsibility for, at its expense, Manufacturing (or having Manufactured) and supplying the Licensed Compounds and Licensed Products for its development and commercialization activities in the Territory. [[AstraZeneca:Organization]] shall be under no obligation to Manufacture (or have Manufactured) Licensed Compounds.

Development Responsibility. Coya, directly or through any Affiliates or Sublicensees, shall have sole responsibility for the conduct of Development activities under this Agreement and shall bear all costs and expenses incurred in connection with such Development activities. Notwithstanding the foregoing, Coya shall use Commercially Reasonable Efforts, either directly or through any Affiliates or Sublicensees, to Develop and obtain Regulatory Approval for at least one Product, in the United States, the Major EU Markets or Japan.

Responsibility. For each of the [[Unknown Identifier]] and ​ Programs, following the completion of the applicable [[Unknown Identifier]] Technology Transfer or ​ Technology Transfer, # Acadia shall be solely responsible, at its sole expense, for all regulatory activities necessary to obtain and maintain Regulatory Approval of the applicable Licensed Products in the Field in the Territory, and # Acadia will own all Regulatory Materials for such Licensed Products in the Field in the Territory, including all Regulatory Approvals, and will be responsible for the payment of fees and all other associated regulatory costs for such Licensed Products in the Field in the Territory.

Following Candidate Selection with respect to a Program, Takeda shall be solely responsible, at its sole cost and expense, for all activities related to the Development and Commercialization of the Licensed Products under such Program and Poseida shall have no right or obligation (including research obligations) to Exploit any such Licensed Products; provided that upon mutual agreement of the Parties, Poseida may perform further research activities with respect to such Program.

Development Responsibility. [[Savara:Organization]] shall have sole responsibility for Developing # a Licensed Product for the Initial Indication in commercially reasonable accordance with the Development Plan and # any Additional Licensed Product for an Additional Indication, elected by [[Savara:Organization]] pursuant to Section 4.1.

Responsibility for Development. As between the Parties, Lilly shall have the sole right and responsibility, at its sole cost and expense, for the conduct of all Development activities in respect of any Product in the Territory.